Newer alternatives for resistant hypertension : Beyond 2022 paradigms
Copyright © 2023 Hellenic Society of Cardiology. Published by Elsevier B.V. All rights reserved..
Given the increased incidence of resistant hypertension and no novel agents to manage hypertension for more than 15 years, there has been an increase in the development of newer agents with unique mechanisms that will hopefully aid in getting this subset of patients under control. More recent classes of agents include nonsteroidal mineralocorticoid receptor blockers, aminopeptidase A inhibitors, dual endothelin A and B antagonists and aldosterone synthetase inhibitors, and novel agents affecting angiotensinogen mRNA in the liver. All these agents are under different levels of development and, if all goes well, should be available to the public within the next 2-5 years. In addition to these agents, renal denervation is anticipated to be approved in the United States within the next 6-9 months, whereas it has already been authorized in certain European countries. Thus, by 2025 and later, we will have a more extensive armamentarium to help quell the rise in resistant hypertension. From early actuarial data associating elevated blood pressure with mortality to the first trials of blood pressure-lowering medications to contemporary American and European hypertension guidelines, the beneficial impact of blood pressure lowering in individuals with hypertension is well established1,2-4. Population-level decreases in incident cardiovascular disease and mortality over the past 50 years reflect this well-established impact. Yet, the year-over-year decline in the incidence of cardiovascular disease has now plateaued, and concomitantly rates of uncontrolled hypertension have increased5,6. Additionally, how the global COVID-19 pandemic impacts cardiovascular disease and hypertension-related outcomes is yet to be determined, but early data suggests population-level increases in blood pressure7.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:70 |
|---|---|
| Enthalten in: |
Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese - 70(2023) vom: 04. März, Seite 75-77 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Laffin, Luke J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Aldosterone |
|---|
| Anmerkungen: |
Date Completed 31.03.2023 Date Revised 31.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.hjc.2023.01.006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352499869 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352499869 | ||
| 003 | DE-627 | ||
| 005 | 20231226053850.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.hjc.2023.01.006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1174.xml |
| 035 | |a (DE-627)NLM352499869 | ||
| 035 | |a (NLM)36739976 | ||
| 035 | |a (PII)S1109-9666(23)00022-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Laffin, Luke J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Newer alternatives for resistant hypertension |b Beyond 2022 paradigms |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.03.2023 | ||
| 500 | |a Date Revised 31.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Hellenic Society of Cardiology. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a Given the increased incidence of resistant hypertension and no novel agents to manage hypertension for more than 15 years, there has been an increase in the development of newer agents with unique mechanisms that will hopefully aid in getting this subset of patients under control. More recent classes of agents include nonsteroidal mineralocorticoid receptor blockers, aminopeptidase A inhibitors, dual endothelin A and B antagonists and aldosterone synthetase inhibitors, and novel agents affecting angiotensinogen mRNA in the liver. All these agents are under different levels of development and, if all goes well, should be available to the public within the next 2-5 years. In addition to these agents, renal denervation is anticipated to be approved in the United States within the next 6-9 months, whereas it has already been authorized in certain European countries. Thus, by 2025 and later, we will have a more extensive armamentarium to help quell the rise in resistant hypertension. From early actuarial data associating elevated blood pressure with mortality to the first trials of blood pressure-lowering medications to contemporary American and European hypertension guidelines, the beneficial impact of blood pressure lowering in individuals with hypertension is well established1,2-4. Population-level decreases in incident cardiovascular disease and mortality over the past 50 years reflect this well-established impact. Yet, the year-over-year decline in the incidence of cardiovascular disease has now plateaued, and concomitantly rates of uncontrolled hypertension have increased5,6. Additionally, how the global COVID-19 pandemic impacts cardiovascular disease and hypertension-related outcomes is yet to be determined, but early data suggests population-level increases in blood pressure7 | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a aldosterone | |
| 650 | 4 | |a future | |
| 650 | 4 | |a hypertension | |
| 650 | 4 | |a population health | |
| 650 | 7 | |a Antihypertensive Agents |2 NLM | |
| 700 | 1 | |a Briasoulis, Alexandros |e verfasserin |4 aut | |
| 700 | 1 | |a Bakris, George L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese |d 2005 |g 70(2023) vom: 04. März, Seite 75-77 |w (DE-627)NLM154585718 |x 2241-5955 |7 nnns |
| 773 | 1 | 8 | |g volume:70 |g year:2023 |g day:04 |g month:03 |g pages:75-77 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.hjc.2023.01.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 70 |j 2023 |b 04 |c 03 |h 75-77 | ||